All articles tagged with #chinese biotech
The Trump administration is considering strict new restrictions on licensing Chinese investigational drugs, including enhanced scrutiny and security reviews, amid concerns over China's growing influence in biotech and medicine, with proposals also to boost US domestic drug production and speed up FDA review processes.
Chinese biotech shares have surged this year, driven by optimism over innovative cancer treatments being licensed to Western pharma companies, with notable deals like 3SBio's with Pfizer and Akeso's competitive PD-1 treatments, amidst a broader industry rebound and lower research costs, despite geopolitical uncertainties.
Negotiators on a key US defense bill decided not to include the Biosecure Act, which would have blacklisted five Chinese-linked biotechnology firms from federally funded research and contracts. Despite earlier support from the House and a bipartisan group in the Senate, senior House Democrats objected to naming specific companies in the legislation, resulting in a win for the Chinese biotech firms.
A proposed biosecurity bill aimed at regulating Chinese biotech contractors, such as WuXi AppTec, was not included in the end-of-year defense package, which was considered its best opportunity for passage in the current session of Congress.
Moderna's shares have risen after the company announced a partnership with Chinese biotech company, BeiGene, to develop and commercialize mRNA-based personalized cancer treatments. The collaboration will focus on developing potential treatments for various types of cancer using Moderna's mRNA technology platform. This partnership marks Moderna's entry into the Chinese market and highlights the growing interest in mRNA-based therapies for cancer treatment.